Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR HFA versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR HFA versus STERI STAT.
ADVAIR HFA vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADVAIR HFA is a combination of fluticasone propionate, a corticosteroid that reduces inflammation by inhibiting multiple inflammatory cell types and mediators, and salmeterol, a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing cAMP levels.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
2 inhalations (fluticasone 230 mcg/salmeterol 21 mcg per inhalation) twice daily, approximately 12 hours apart, via oral inhalation. Maximum: 2 inhalations twice daily.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Fluticasone propionate: 7.8 hours (inhalation), prolonged in hepatic impairment. Salmeterol: 5.5 hours.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Fluticasone propionate: Renal <5%, fecal (primarily as metabolites) ~90%. Salmeterol: Renal 25% (as metabolites), fecal 60%.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid